Do you want to read an article? Please log in or register.
Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis
Psoriatic ArthritisSpinal Disorders
COMMENTED
Related content
Rheumatoid Arthritis
Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Rheumatology (Oxford).
Leu JH, Adedokun OJ, Gargano C, Hsia EC, Xu Z, Shankar G
doi: 10.1093/rheumatolog/key309.
Psoriasis
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
JAMA Dermatol
Elewski BE, Baddley JW, Deodhar AA, Magrey M, Rich PA, Soriano ER, Soung J, Bao W, Keininger D, Marfo K, Patekar M, Sharma A, Shete A, Lebwohl MG
doi: 10.1001/jamadermatol.2020.3257
PsoriasisPsoriatic ArthritisSpinal Disorders
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Ann Rheum Dis.
Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, Porter B, Das Gupta A, Pricop L, Fox T
doi: 10.1136/annrheumdis-2018-214273.
Psoriatic ArthritisRheumatoid ArthritisSpinal Disorders
Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany
Rheumatol Int.
Krüger K, Burmester GR, Wassenberg S, Bohl-Bühler M, Thomas MH
doi: 10.1007/s00296-018-4180-4.
Psoriatic Arthritis
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
Rheumatology (Oxford).
Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD
doi: 10.1093/
Psoriatic Arthritis
Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients
Rheumatology (Oxford)
Onac IA, Clarke BD, Tacu C, Lloyd M, Hajela V, Batty T, Thoroughgood J, Smith S, Irvine H, Hill D, Baxter G, Horwood N, Mahendrakar S, Rajak R, Griffith S, Kiely PDW, Galloway J
doi: 10.1093/rheumatology/keab193
Psoriasis
The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and post-marketing surveillance data
Br J Dermatol
Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W, Jehl V, Marfo K, Primatesta P, Shete A, Trivedi V, Mease PJ
doi: 10.1111/bjd.20136
COMMENTED
Psoriatic Arthritis
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
Rheumatology (Oxford).
van der Heijde D, Mease PJ, Landewé RBM, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofu S, Pricop L
doi: 10.1093/rheumatology/kez420.
Psoriatic ArthritisRheumatoid Arthritis
Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study.
Rheumatol Int.
Nissen CB, Hørslev-Petersen K, Primdahl J